NSE: MARKSANS | BSE: 524404

Strong Performer, Getting Expensive

Download real time

320.85 -6.15 (-1.88%)

New 52W High in past week

2.1M NSE+BSE Volume

NSE 20 Aug, 2026 3:53 PM (IST)

14,539.8

Market Cap

High in industry

Beta 1Year

Average volatility

Dividend

Marksans Pharma last dividend of ₹0.900 per share was given on 20 Aug 2026 See details

Marksans Pharma Ltd. share price target and research reports

Name: Latest research reports of Marksans Pharma Ltd. authored by Ventura and published by - Trendlyne research reports.
Item: Marksans Pharma Ltd.
Rating: 5
Author: Ventura

Latest analyst research reports with target prices and PDF download for MARKSANS, BSE:524404 Marksans Pharma Ltd.

Search Inside the pdf :

Marksans Pharma Ltd.

14 Mar 2024

320.85

-1.88%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Growth in demand and capabilities

Marksans Pharma Ltd. is trading above all available SMAs

Marksans Pharma Ltd.

04 Oct 2023

320.85

-1.88%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Consolidating on the back of the Teva acquisition

Marksans Pharma has gained 47.65% in the last 3 Months

Marksans Pharma Ltd.

22 Jul 2023

320.85

-1.88%

Strong growth in OTC business to drive profitability

Buy: Marksans Pharma Ltd.

StoxBox - BP Wealth

Marksans Pharma has entered into a Business Transfer Agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations in Goa. The company plans to manufacture tablets, hard and soft gel capsules, ointments, gummies, and creams from the new capacity.

Marksans Pharma has gained 20.12% in the last 1 Month

Marksans Pharma Ltd.

21 Oct 2022

320.85

-1.88%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Ventura

Growth visibility with reasonable valuation

Number of FII/FPI investors increased from 145 to 162 in Jun 2026 qtr.

Marksans Pharma Ltd.

06 Jun 2022

320.85

-1.88%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Target

Arihant Capital

Marksans Pharma Ltd. is trading above all available SMAs

Marksans Pharma Ltd.

14 Oct 2021

320.85

-1.88%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Arihant Capital

We had hosted Investor Conference on 29th & 30th September 2021 where 15 companies participated at our Arihant Rising Star's Virtual Summit. Key takeaways from the conference are as follows:...

Number of FII/FPI investors increased from 145 to 162 in Jun 2026 qtr.

Marksans Pharma Ltd.

11 Jun 2018

320.85

-1.88%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Source: Bloomberg, Centrum Research, *as on 8th June 2018 Recommendation and key risks: We have revised our FY19E and FY20E EPS downwards by 41% and 43% respectively. We downgrade MPL to Hold from Buy rating, with a TP of Rs31 based on 18x March'20E EPS of Rs1.7, and a 10.2%% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA...

Marksans Pharma Ltd. is trading above all available SMAs

Marksans Pharma Ltd.

11 Jun 2018

320.85

-1.88%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Number of FII/FPI investors increased from 145 to 162 in Jun 2026 qtr.

Marksans Pharma Ltd.

19 Feb 2018, 12:00AM

320.85

-1.88%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Recommendation and key risks: We have revised our FY18E and FY19E EPS downwards by 3% and 19% respectively. We upgrade MPL to Buy from Hold rating, with a TP of Rs55 based on 18x March'20E EPS of Rs3.0, and a 45.3% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA and...

Marksans Pharma has gained 74.11% in the last 1 Year

Is Marksans Pharma Ltd. worth buying?

1448 Votes:

Buy 80.73%

Sell 10.01%

Hold 9.25%